Hoersholm, Denmark, March 21th 2017
Hoersholm, Denmark, March 21th, 2017 – Oncology Venture Sweden AB (OV:ST) today announced that the Danish Medicines Agencies (DHMA) have approved the focused APO010 Multiple Myeloma study. APO010 is a first-in-class FAS-ligand anticancer product in the immuno-oncology field.
The DRP Screening for sensitive patients at four centers of Multiple Myeloma patients is already ongoing for the study with Oncology Ventures Immuno-Oncology drug APO010. In total 150 evaluable patients, will be screened using OV’s DRPTM (Drug Response Predictor) with the aim to identify 15 Multiple Myeloma patients with the highest likelihood to benefit from treatment with APO010. The APO010 product has already been manufactured for two clinical trials. The study will be initiated during May 2017 and recruit patients during the 12 following month.